ALLEN, Texas, May 23, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.15 per share on its outstanding shares of Common Stock. This dividend will be payable on June 30, 2023 to stockholders of record at the close of business on June 15, 2023.
Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.
| Contact: | Cindy Ferguson |
| Vice President and Chief Financial Officer | |
| (972) 390-9800 |
| Last Trade: | US$459.92 |
| Daily Volume: | 0 |
| Market Cap: | US$809.460M |
August 08, 2024 May 28, 2024 May 10, 2024 February 29, 2024 November 07, 2023 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
